AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16154442 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-hour continuous intralipid infusion (20%, 0.4 mg mL(‐1) h(‐1))
Number of subjects: 40
Study 16154442 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion (control)
Number of subjects: 40
Study 12949284 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion (CSII)
Number of subjects: 23
Study 12949284 — intervention group
Group type: COMPARATOR
Intervention: Multiple daily insulin injections (MDI)
Number of subjects: 23
Study 10895854 — intervention group
Group type: EXPERIMENTAL
Intervention: Pinitol 20 mg x kg(‐1) x day(‐1) (n = 12)
Number of subjects: 22
Study 10895854 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 10)
Number of subjects: 22
Study 8797646 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-cm J-pouch (5-J group)
Number of subjects: 40
Study 8797646 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-cm J-pouch (10-J group)
Number of subjects: 40
Study 1622179 — intervention group
Group type: EXPERIMENTAL
Intervention: Fleroxacin (400 mg every 24 h)
Number of subjects: 12
Study 1622179 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (500 mg every 12 h)
Number of subjects: 12
Study 1622179 — intervention group
Group type: COMPARATOR
Intervention: Comparison of Fleroxacin and Ciprofloxacin
Number of subjects: 12
Study 6541251 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (120 mg/day)
Number of subjects: 12
Study 6541251 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 6541251 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 12
Study 30600794 — intervention group
Group type: EXPERIMENTAL
Intervention: Meaning and Purpose (MaP) therapy
Number of subjects: 57
Study 30600794 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 57
Study 29129894 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized daughter-directed reminder leaflet for cervical cancer screening.
Number of subjects: 2548
Study 29129894 — intervention group
Group type: COMPARATOR
Intervention: Combination package containing a personalized daughter-directed reminder leaflet and an additional informational leaflet for the mother requesting her recommendation for screening.
Number of subjects: 2548
Study 26897630 — intervention group
Group type: EXPERIMENTAL
Intervention: Condolence letter sent 15 days after death
Number of subjects: 264
Study 26897630 — intervention group
Group type: COMPARATOR
Intervention: No condolence letter (control)
Number of subjects: 264
Study 25213203 — intervention group
Group type: EXPERIMENTAL
Intervention: Early post-exercise imaging (Stress-1)
Number of subjects: 229
Study 22330025 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body vibration therapy (9-15 min, frequency = 20-30 Hz, amplitude = 0.44-0.60 mm)
Number of subjects: 82
Study 22330025 — intervention group
Group type: COMPARATOR
Intervention: Leg exercises without vibration (control group)
Number of subjects: 82
Study 22330025 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body vibration therapy
Number of subjects: 82
Study 19265567 — intervention group
Group type: EXPERIMENTAL
Intervention: Compulsory community treatment orders
Number of subjects: 0
Study 19265567 — intervention group
Group type: COMPARATOR
Intervention: Parliament's responsibility
Number of subjects: 0
Study 17632305 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm compress (44.4‐45 degrees C) applied for 30 min to the closed eyelids of the experimental eye
Number of subjects: 24
Study 17632305 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm compress protocol repeated to investigate the Fischer‐Schweitzer polygonal reflex
Number of subjects: 24
Study 15376806 — intervention group
Group type: EXPERIMENTAL
Intervention: Teaching predictive values of features (central or peripheral) for biological properties of animals
Number of subjects: 0
Study 11400949 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled fluticasone propionate, 880 microg every 12 hours for 12 weeks from the start date of their CPB conditioning regimen.
Number of subjects: 63
Study 11400949 — intervention group
Group type: COMPARATOR
Intervention: Historical control group of 45 consecutive breast cancer patients undergoing ASCT with CPB as a conditioning regimen.
Number of subjects: 63
Study 9744697 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg sublingual glyceryl trinitrate (GTN)
Number of subjects: 20
Study 9744697 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 7756937 — intervention group
Group type: EXPERIMENTAL
Intervention: Instrumentation Laboratories reagent
Number of subjects: 40
Study 7756937 — intervention group
Group type: EXPERIMENTAL
Intervention: Manchester low-opacity reagent
Number of subjects: 40
Study 3164051 — intervention group
Group type: EXPERIMENTAL
Intervention: Nalbuphine
Number of subjects: 50
Study 3164051 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl
Number of subjects: 50
Study 28420282 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavior Therapy (CBT)
Number of subjects: 32
Study 28420282 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 32
Study 26413933 — intervention group
Group type: EXPERIMENTAL
Intervention: Fever control
Number of subjects: 135
Study 26413933 — intervention group
Group type: COMPARATOR
Intervention: Mild therapeutic hypothermia (MTH)
Number of subjects: 135
Study 25536598 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy combined with h-R3
Number of subjects: 35
Study 25536598 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 35
Study 23525426 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Number of subjects: 66
Study 23525426 — intervention group
Group type: COMPARATOR
Intervention: Voglibose
Number of subjects: 66
Study 23525426 — intervention group
Group type: EXPERIMENTAL
Intervention: Alogliptin
Number of subjects: 66
Study 20427917 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (TENS) - 50 Hz, pulse width 0.5 mSec, intensity 0‐60 mA for 20 minutes for a period of seven days
Number of subjects: 60
Study 20427917 — intervention group
Group type: COMPARATOR
Intervention: Microcurrent electrical nerve stimulation (MENS) - 0.5 Hz, intensity 1,000 muA for 20 minutes for a period of seven days
Number of subjects: 60
Study 18722631 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil 2.5 mg
Number of subjects: 1058
Study 18722631 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil 5 mg
Number of subjects: 1058
Study 18722631 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil 10 mg
Number of subjects: 1058
Study 18722631 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil 20 mg
Number of subjects: 1058
Study 18722631 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1058
Study 18722631 — intervention group
Group type: EXPERIMENTAL
Intervention: All Tadalafil doses
Number of subjects: 1058
Study 15778231 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard treatment plus stabilising exercises
Number of subjects: 386
Study 15778231 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard treatment plus acupuncture
Number of subjects: 386
Study 15778231 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 386
Study 12870339 — intervention group
Group type: EXPERIMENTAL
Intervention: Hunan aqueous drainage (HAD) implantation with mitomycin C (MMC) (0.4 mg/ml, 1 to 5 mins)
Number of subjects: 154
Study 12870339 — intervention group
Group type: COMPARATOR
Intervention: Hunan aqueous drainage (HAD) implantation without mitomycin C (MMC)
Number of subjects: 154
Study 12870339 — intervention group
Group type: EXPERIMENTAL
Intervention: HAD implantation with MMC
Number of subjects: 154
Study 12870339 — intervention group
Group type: EXPERIMENTAL
Intervention: HAD implantation
Number of subjects: 154
Study 10572768 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain Tracker
Number of subjects: 79
Study 10572768 — intervention group
Group type: COMPARATOR
Intervention: Control group (no Pain Tracker)
Number of subjects: 79
Study 8757659 — intervention group
Group type: EXPERIMENTAL
Intervention: Automatic beam quality selection (OPDOSE) with 26 kVp and a tungsten target with rhodium filtration
Number of subjects: 0
Study 8757659 — intervention group
Group type: COMPARATOR
Intervention: Manually selected tube potentials with a molybdenum/molybdenum target filter combination
Number of subjects: 0
Study 8757659 — intervention group
Group type: EXPERIMENTAL
Intervention: Automatic beam quality selection (OPDOSE)
Number of subjects: 0
Study 1820893 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyrimethamine 50mg
Number of subjects: 12
Study 7129748 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine infusions over a two-year period
Number of subjects: 1
Study 7129748 — intervention group
Group type: COMPARATOR
Intervention: Single-blind placebo infusion
Number of subjects: 1
Study 7129748 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine infusions
Number of subjects: 1
Study 30696812 — intervention group
Group type: EXPERIMENTAL
Intervention: Variants in the ADGRL3 (LPHN3) gene
Number of subjects: 2698
Study 30696812 — intervention group
Group type: EXPERIMENTAL
Intervention: rs4860437 variant
Number of subjects: 2698
Study 30696812 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic models
Number of subjects: 2698
Study 28942805 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialectical Behavior Therapy for Children (DBT-C)
Number of subjects: 43
Study 28942805 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 43
Study 26424477 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula milk with an ω‐6/ω‐3 ratio of 2/1 (Group A)
Number of subjects: 45
Study 26424477 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula milk with an ω‐6/ω‐3 ratio of 1/1 (Group B)
Number of subjects: 45
Study 23013235 — intervention group
Group type: EXPERIMENTAL
Intervention: Academic information condition
Number of subjects: 721
Study 23013235 — intervention group
Group type: EXPERIMENTAL
Intervention: Health information condition
Number of subjects: 721
Study 23013235 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 721
Study 21931861 — intervention group
Group type: EXPERIMENTAL
Intervention: MEMA kwa Vijana adolescent sexual and reproductive health intervention
Number of subjects: 13814
Study 21931861 — intervention group
Group type: COMPARATOR
Intervention: Comparison schools (control)
Number of subjects: 13814
Study 19525833 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquatic exercise (20 sessions, 5 times per week for 4 weeks in a swimming pool at 33 degrees C)
Number of subjects: 65
Study 19525833 — intervention group
Group type: COMPARATOR
Intervention: Land-based exercise (home-based exercise, demonstrated by a physiotherapist once with written advice)
Number of subjects: 65
Study 15834219 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose alcoholic beverage (0.4 g/kg)
Number of subjects: 16
Study 15834219 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose alcoholic beverage (0.8 g/kg)
Number of subjects: 16
Study 15834219 — intervention group
Group type: COMPARATOR
Intervention: Placebo (1% ethanol as a taste mask)
Number of subjects: 16
Study 15834219 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (both doses)
Number of subjects: 16
Study 12867885 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1 with PAD
Number of subjects: 150
Study 12867885 — intervention group
Group type: COMPARATOR
Intervention: Group 0 without PAD
Number of subjects: 150
Study 12867885 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of albuminuria and retinopathy
Number of subjects: 150
Study 12867885 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistive index (RI)
Number of subjects: 150
Study 10862538 — intervention group
Group type: EXPERIMENTAL
Intervention: OCCL for 3 min
Number of subjects: 9
Study 10862538 — intervention group
Group type: COMPARATOR
Intervention: Non-OCCL
Number of subjects: 9
Study 8880362 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulating amnesia (n = 12 and n = 15)
Number of subjects: 41
Study 8880362 — intervention group
Group type: COMPARATOR
Intervention: Control group not simulating amnesia (n = 14)
Number of subjects: 41
Study 1907056 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem (90-360 mg per day based on body weight)
Number of subjects: 30
Study 1907056 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 6322505 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole 400 mg/day for 3 days
Number of subjects: 140
Study 6322505 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole 200 mg/day for 6 days
Number of subjects: 140
Study 6322505 — intervention group
Group type: COMPARATOR
Intervention: Miconazole 100 mg/day for 14 days
Number of subjects: 140
Study 31604631 — intervention group
Group type: EXPERIMENTAL
Intervention: Dosing cups
Number of subjects: 493
Study 31604631 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral syringes
Number of subjects: 493
Study 28274772 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg three times daily for 5 days
Number of subjects: 51
Study 28274772 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 25690774 — intervention group
Group type: EXPERIMENTAL
Intervention: Gans repositioning maneuver with postmaneuver restrictions (GRMR)
Number of subjects: 45
Study 25690774 — intervention group
Group type: EXPERIMENTAL
Intervention: Gans repositioning maneuver (GRM)
Number of subjects: 45
Study 25690774 — intervention group
Group type: COMPARATOR
Intervention: Canalith repositioning maneuver (CRM)
Number of subjects: 45
Study 24284414 — intervention group
Group type: EXPERIMENTAL
Intervention: Once daily mesalazine
Number of subjects: 58
Study 24284414 — intervention group
Group type: COMPARATOR
Intervention: Three times daily mesalazine
Number of subjects: 58
Study 24284414 — intervention group
Group type: EXPERIMENTAL
Intervention: General adherence measures
Number of subjects: 58
Study 22682806 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine (Gem) treatment arm with CA 19-9 <90 U/mL
Number of subjects: 0
Study 22682806 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine (Gem) treatment arm with CA 19-9 ≥90 U/mL
Number of subjects: 0
Study 22682806 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine (Gem) treatment arm with RT quality assurance per protocol and CA 19-9 <90 U/mL
Number of subjects: 0
Study 22682806 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine (Gem) arm of the CONKO trial
Number of subjects: 0
Study 22682806 — intervention group
Group type: EXPERIMENTAL
Intervention: CA 19-9 serum level ≥90 U/mL
Number of subjects: 0
Study 19125777 — intervention group
Group type: EXPERIMENTAL
Intervention: Vildagliptin (50 mg twice daily)
Number of subjects: 2789
Study 19125777 — intervention group
Group type: COMPARATOR
Intervention: Glimepiride (titrated up to 6 mg/day, mean dose 4.5 mg/day)
Number of subjects: 2789
Study 17381394 — intervention group
Group type: EXPERIMENTAL
Intervention: Ertapenem (1 g qd)
Number of subjects: 494
Study 17381394 — intervention group
Group type: COMPARATOR
Intervention: Piperacillin/tazobactam (3.375 g q6h)
Number of subjects: 494
Study 15978925 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular aneurysm repair (EVAR)
Number of subjects: 1082
Study 15978925 — intervention group
Group type: COMPARATOR
Intervention: Open repair
Number of subjects: 1082
Study 12699137 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedical home blood pressure (HBP) measurement
Number of subjects: 362
Study 12699137 — intervention group
Group type: COMPARATOR
Intervention: Clinic blood pressure (CBP) measurement
Number of subjects: 362
Study 10402160 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrice‐weekly buprenorphine dose schedules (64, 84, and 112 mg weekly)
Number of subjects: 10
Study 10402160 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily buprenorphine dose of 16 mg/70 kg
Number of subjects: 10
Study 10402160 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrice‐weekly buprenorphine dose schedules
Number of subjects: 10
Study 8684155 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperventilation provocation test (HVPT)
Number of subjects: 115
Study 8684155 — intervention group
Group type: COMPARATOR
Intervention: Placebo test (isocapnic overbreathing)
Number of subjects: 115
Study 8684155 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulatory transcutaneous monitoring of pCO2
Number of subjects: 115
Study 1745842 — intervention group
Group type: EXPERIMENTAL
Intervention: Standing position
Number of subjects: 94
Study 1745842 — intervention group
Group type: COMPARATOR
Intervention: Sitting position
Number of subjects: 94
Study 12265803 — intervention group
Group type: EXPERIMENTAL
Intervention: ML Cu 250-standard
Number of subjects: 375
Study 12265803 — intervention group
Group type: COMPARATOR
Intervention: ML Cu 250-short
Number of subjects: 375
Study 30168408 — intervention group
Group type: EXPERIMENTAL
Intervention: Memory strategy training
Number of subjects: 60
Study 30168408 — intervention group
Group type: COMPARATOR
Intervention: Control memory training
Number of subjects: 60
Study 27783532 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil thermosensitive vaginal gel
Number of subjects: 0
Study 26265452 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation intervention (n = 30)
Number of subjects: 60
Study 26265452 — intervention group
Group type: COMPARATOR
Intervention: Sham transcranial magnetic stimulation intervention (n = 30)
Number of subjects: 60
Study 24327037 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP
Number of subjects: 194
Study 24327037 — intervention group
Group type: COMPARATOR
Intervention: Control (no CPAP)
Number of subjects: 194
Study 21251653 — intervention group
Group type: EXPERIMENTAL
Intervention: LMWH (enoxaparin 40 mg, once daily) plus LDA
Number of subjects: 60
Study 21251653 — intervention group
Group type: COMPARATOR
Intervention: UFH (5000 units, twice daily) plus LDA
Number of subjects: 60
Study 21251653 — intervention group
Group type: EXPERIMENTAL
Intervention: LMWH plus LDA
Number of subjects: 60
Study 21251653 — intervention group
Group type: COMPARATOR
Intervention: UFH plus LDA
Number of subjects: 60
Study 18482635 — intervention group
Group type: EXPERIMENTAL
Intervention: Highly visible CPP display
Number of subjects: 100
Study 18482635 — intervention group
Group type: COMPARATOR
Intervention: Control group (without additional CPP display)
Number of subjects: 100
Study 16253973 — intervention group
Group type: EXPERIMENTAL
Intervention: Elective single embryo transfer (eSET)
Number of subjects: 308
Study 16253973 — intervention group
Group type: COMPARATOR
Intervention: Double embryo transfer (DET)
Number of subjects: 308
Study 16253973 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard policy for eSET (SP-eSET)
Number of subjects: 308
Study 16253973 — intervention group
Group type: COMPARATOR
Intervention: Standard policy for double embryo transfer (SP-DET)
Number of subjects: 308
Study 16253973 — intervention group
Group type: COMPARATOR
Intervention: Standard policy for eSET and DET
Number of subjects: 308
Study 12705778 — intervention group
Group type: EXPERIMENTAL
Intervention: TEOAEs in elderly subjects (n=45)
Number of subjects: 232
Study 12705778 — intervention group
Group type: COMPARATOR
Intervention: Control group of normal-hearing young adults (n=20)
Number of subjects: 232
Study 12705778 — intervention group
Group type: EXPERIMENTAL
Intervention: TEOAEs presence in left ears
Number of subjects: 232
Study 12705778 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjects with PTA above 40 dB HL
Number of subjects: 232
Study 12705778 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgroup with TEOAEs
Number of subjects: 232
Study 12705778 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall response level and overall reproducibility
Number of subjects: 232
Study 12705778 — intervention group
Group type: EXPERIMENTAL
Intervention: Average hearing level
Number of subjects: 232
Study 10749603 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal 5-fluorouracil (5-FU) administered at 0.6 g/m2/day for 6 days (day 4 to day 10) plus intravenous 5-FU (1 g) during surgery
Number of subjects: 267
Study 10749603 — intervention group
Group type: COMPARATOR
Intervention: Resection alone (Control group)
Number of subjects: 267
Study 10749603 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal 5-FU (full treatment)
Number of subjects: 267
Study 9361576 — intervention group
Group type: EXPERIMENTAL
Intervention: Diphenhydramine (n = 32)
Number of subjects: 98
Study 9361576 — intervention group
Group type: EXPERIMENTAL
Intervention: Loratadine (n = 33)
Number of subjects: 98
Study 9361576 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 33)
Number of subjects: 98
Study 1525128 — intervention group
Group type: EXPERIMENTAL
Intervention: 60% phosphoric acid gel with 0.5% NaF (Orthoprep) for 5 seconds
Number of subjects: 75
Study 1525128 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthoprep for 15 seconds
Number of subjects: 75
Study 1525128 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthoprep for 30 seconds
Number of subjects: 75
Study 1525128 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthoprep for 60 seconds
Number of subjects: 75
Study 1525128 — intervention group
Group type: COMPARATOR
Intervention: 37% non‐fluoridated phosphoric acid gel (Coe) for 60 seconds
Number of subjects: 75
Study 2865027 — intervention group
Group type: EXPERIMENTAL
Intervention: Dezocine
Number of subjects: 10
Study 2865027 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine
Number of subjects: 10
Study 2865027 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 29431455 — intervention group
Group type: EXPERIMENTAL
Intervention: 90-minute Prolonged Exposure therapy sessions
Number of subjects: 160
Study 29431455 — intervention group
Group type: COMPARATOR
Intervention: 60-minute Prolonged Exposure therapy sessions
Number of subjects: 160
Study 28323164 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (250mg)
Number of subjects: 16
Study 28323164 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 25858265 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease activity guided dose reduction of adalimumab or etanercept
Number of subjects: 180
Study 25858265 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 180